Explore evidence

24 %161 (24%) of samples yielded a detectable viral load (>400 copies/mL).

CamerounVIH/sidapublished 2012Journal of the International AIDS Societyeurope_pmcdocument of 39 observations

8,396 adultsDuring the Family Health Days campaign from 17th October to 25th November 2011, 8,396 adults were tested for HIV.

CamerounVIH/sidaobserved 17th October to 25th November 2011published 2012Journal of the International AIDS Societyeurope_pmcdocument of 39 observations

38.5 %At endpoint, 38.5% of 141 HIV-infected adult patients were lost to follow-up.

CamerounVIH/sidaobserved 2009-2011published 2013PLoS ONEOpenAlexdocument of 8 observationsDOI 10.1371/journal.pone.0072680

143 participantsA total of 143 HIV-infected Cameroonians aged 21 years or above were recruited in the study.

CamerounVIH/sidapublished 2013Diabetes & metabolismeurope_pmcdocument of 12 observations

82.4 %The prevalence of virological suppression was 82.4% overall among adult patients receiving antiretroviral therapy in the Centre and Littoral regions of Cameroon.

CamerounVIH/sidapublished 2019HIV medicineeurope_pmcdocument of 5 observationsDOI 10.1111/hiv.12681

7.8 %Adult HIV prevalence (≥18 years) was 7.8% in 2011 (179/2,282 adults).

CamerounVIH/sidaobserved 2011published 2012Journal of the International AIDS Societyeurope_pmcdocument of 39 observations

23.6 %Among 407 patients on first-line antiretroviral treatment in rural Cameroon, 96 (23.6%) had unsuppressed viral load.

CamerounVIH/sidaobserved 2013-2014published 2016Open Forum Infectious Diseaseseurope_pmcdocument of 3 observations

0.43 SMDAmong HIV+ individuals, antiretroviral therapy use was associated with higher low-density lipoprotein with a standardized mean difference of 0.43.

Camerounlow-density lipoprotein · VIH/sidapublished 2013International journal of epidemiologyeurope_pmcdocument of 10 observationsDOI 10.1093/ije/dyt198

10.4 %Pretreatment HIV drug resistance (PDR) prevalence among all antiretroviral therapy (ART) initiators in Cameroon was 10.4% (95% CI 5.4%–19.1%).

CamerounVIH/sidaobserved 2015published 2018Journal of Antimicrobial ChemotherapyOpenAlexdocument of 12 observationsDOI 10.1093/jac/dky221

142 isolatesNo major mutations associated with resistance to nucleoside reverse transcriptase inhibitors (NRTIs) or protease inhibitors were detected in 142 HIV-1 isolates from antiretroviral-naive patients.

CamerounVIH/sidapublished 2000Journal of Clinical MicrobiologyOpenAlexdocument of 19 observations

10.4 %Among ART initiators with no prior exposure to antiretrovirals in Cameroon, pretreatment HIV drug resistance (PDR) prevalence was 10.4% (95% CI 4.7%–21.5%).

CamerounVIH/sidaobserved 2015published 2018Journal of Antimicrobial ChemotherapyOpenAlexdocument of 12 observationsDOI 10.1093/jac/dky221

2 %The prevalence of the 333E substitution in reverse transcriptase sequences was 2% among 57 HIV-1-infected treatment-naive individuals from Cameroon.

CamerounVIH/sidapublished 2011AIDS Research and Human RetrovirusesOpenAlexdocument of 24 observations

107 strainsAmong 110 HIV-1-infected, drug-naïve Cameroonians, secondary PI resistance-associated mutations were found in all samples except one strain of subtype B and two strains of CRF02-AG.

CamerounVIH/sidapublished 2002Journal of Clinical MicrobiologyOpenAlexdocument of 12 observations

1.21 hazard_ratioHIV-positive patients with disease symptoms had a hazard ratio of 1.21 for early antiretroviral treatment initiation.

CamerounVIH/sidaobserved 2014published 2020Health Policy and PlanningOpenAlexdocument of 6 observationsDOI 10.1093/heapol/czaa153

5.6 %Only 5.6% of the 142 strains, all belonging to subtype B or D, had no mutations in the protease gene.

CamerounVIH/sidapublished 2000Journal of Clinical MicrobiologyOpenAlexdocument of 19 observations

11.2 %The K20M/R mutation was identified in 11.2% of the 142 HIV-1 isolates in the protease gene.

CamerounVIH/sidapublished 2000Journal of Clinical MicrobiologyOpenAlexdocument of 19 observations

2.3 %Among 128 patients routinely receiving highly active antiretroviral therapy in an HIV/AIDS outpatient clinic in Cameroon, 2.3% had resistance to protease inhibitors.

CamerounVIH/sidapublished 2006Emerging infectious diseasesOpenAlexdocument of 4 observationsDOI 10.3201/eid1206.050860

72.6 %Of 157 coinfected patients, 114 (72.6%) had a HBV viral load < 10 IU/mL.

Camerounhépatite B · VIH/sidapublished 2020BMC Infectious DiseasesOpenAlexdocument of 7 observationsDOI 10.1186/s12879-020-4784-7

63.3 %Among patients with VL ≥ 1000 copies/ml, HIV drug resistance was identified in 63.3% of ART 12-24 patients.

CamerounVIH/sidapublished 2018EClinicalMedicineeurope_pmcdocument of 6 observations

0 %In Yaoundé, the capital city of Cameroon, the prevalence of WHO-defined transmitted HIV-1 drug resistance mutations (DRMs) among ART-naive individuals was 0.0% in 1996–1999.

CamerounVIH/sidaobserved 1996–1999published 2011AIDS (London, England)europe_pmcdocument of 5 observationsDOI 10.1097/qad.0b013e32834bbbe9

3.1 %Among 458 patients who initiated antiretroviral therapy in rural district hospitals in Cameroon between 2006 and 2008, 14 (3.1%) classified at WHO clinical stage 4 had a CD4 count above 350 cells/mm³.

CamerounVIH/sidaobserved 2006-2008published 2010Tropical medicine & international health : TM & IHeurope_pmcdocument of 7 observations

11.1 %Over 5,504 person-years, 414 patients died (11.1%).

CamerounVIH/sidapublished 2012Journal of the International AIDS Societyeurope_pmcdocument of 39 observations

8.6 %Among hospitalized and STI patients, the prevalence of HIV infection was 8.6%.

CamerounVIH/sidapublished 2010RetrovirologyOpenAlexdocument of 3 observationsDOI 10.1186/1742-4690-7-39

8 %The prevalence of antiretroviral drug resistance among patients on first-line ART in rural Cameroon increased from 8.0% in the 6- to 12-month group to 27.1% in the >72-month group.

CamerounVIH/sidaobserved 2013-2014published 2016Open Forum Infectious DiseasesOpenAlexdocument of 5 observationsDOI 10.1093/ofid/ofw233

67.8 %Crude, three-year retention was 67.8% (95% CI: 64.6–70.7) at health centers.

CamerounVIH/sidapublished 2012Journal of the International AIDS Societyeurope_pmcdocument of 39 observations